Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)

V. Patel, M. J. W. Mcphail, A. Zamalloa, S. Stoy, G. M. Vijay, X. Huang, G. Rogers, J. Choo, L. Edwards, E. Gray, C. Woodhouse, S. Gencer, M. Coen, J. Wendon, K. Bruce, D. Shawcross

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)S107-S108
JournalJournal of Hepatology
Publication statusPublished - Apr 2018

Cite this